Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Total Liabilities: 2014-2025

Historic Total Liabilities for ImmunityBio (IBRX) over the last 11 years, with Sep 2025 value amounting to $1.0 billion.

  • ImmunityBio's Total Liabilities fell 5.98% to $1.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 billion, marking a year-over-year decrease of 5.98%. This contributed to the annual value of $871.1 million for FY2024, which is 20.11% down from last year.
  • Per ImmunityBio's latest filing, its Total Liabilities stood at $1.0 billion for Q3 2025, which was up 7.25% from $971.9 million recorded in Q2 2025.
  • ImmunityBio's 5-year Total Liabilities high stood at $1.1 billion for Q2 2024, and its period low was $394.8 million during Q1 2021.
  • In the last 3 years, ImmunityBio's Total Liabilities had a median value of $971.9 million in 2025 and averaged $987.9 million.
  • Its Total Liabilities has fluctuated over the past 5 years, first soared by 1,516.03% in 2021, then declined by 20.11% in 2024.
  • Quarterly analysis of 5 years shows ImmunityBio's Total Liabilities stood at $712.8 million in 2021, then rose by 13.94% to $812.2 million in 2022, then surged by 34.26% to $1.1 billion in 2023, then decreased by 20.11% to $871.1 million in 2024, then declined by 5.98% to $1.0 billion in 2025.
  • Its Total Liabilities stands at $1.0 billion for Q3 2025, versus $971.9 million for Q2 2025 and $894.2 million for Q1 2025.